Wall Street analysts expect CRISPR Therapeutics AG (NASDAQ:CRSP) to post $4.99 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for CRISPR Therapeutics' earnings, with the highest sales estimate coming in at $13.70 million and the lowest estimate coming in at $400,000.00. CRISPR Therapeutics reported sales of $160,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 3,018.8%. The firm is scheduled to announce its next earnings report on Tuesday, April 27th.
On average, analysts expect that CRISPR Therapeutics will report full year sales of $28.35 million for the current year, with estimates ranging from $1.60 million to $90.00 million. For the next year, analysts expect that the business will report sales of $66.74 million, with estimates ranging from $3.50 million to $153.50 million. Zacks' sales averages are a mean average based on a survey of research analysts that cover CRISPR Therapeutics.
CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, February 15th. The company reported ($1.50) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.23). The company had revenue of $0.37 million during the quarter, compared to analysts' expectations of $4.69 million. CRISPR Therapeutics had a negative net margin of 273.10% and a negative return on equity of 20.72%.
CRSP has been the topic of several analyst reports. Barclays boosted their price target on shares of CRISPR Therapeutics from $113.00 to $140.00 and gave the stock an "overweight" rating in a report on Monday, March 8th. The Goldman Sachs Group reduced their target price on CRISPR Therapeutics from $193.00 to $189.00 and set a "neutral" rating for the company in a report on Wednesday, February 17th. Wells Fargo & Company lowered CRISPR Therapeutics from an "overweight" rating to an "equal weight" rating and lifted their price target for the stock from $102.63 to $145.00 in a report on Monday, December 7th. JMP Securities initiated coverage on CRISPR Therapeutics in a research report on Wednesday, March 10th. They issued an "outperform" rating and a $160.00 price objective on the stock. Finally, Zacks Investment Research lowered CRISPR Therapeutics from a "hold" rating to a "sell" rating and set a $177.00 target price for the company. in a research report on Monday, February 1st. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have issued a buy rating to the company's stock. The company currently has an average rating of "Hold" and a consensus target price of $159.94.
Shares of CRSP stock opened at $121.99 on Tuesday. The firm has a 50-day moving average of $128.34 and a 200-day moving average of $131.84. CRISPR Therapeutics has a one year low of $39.25 and a one year high of $220.20. The company has a market cap of $9.20 billion, a P/E ratio of -37.42 and a beta of 2.37.
In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 27,500 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, January 19th. The stock was sold at an average price of $204.94, for a total transaction of $5,635,850.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bradley J. Phd Bolzon sold 30,374 shares of the company's stock in a transaction dated Monday, March 22nd. The shares were sold at an average price of $132.37, for a total value of $4,020,606.38. Following the sale, the director now owns 57,149 shares in the company, valued at $7,564,813.13. The disclosure for this sale can be found here. Insiders have sold a total of 102,874 shares of company stock worth $19,309,856 over the last 90 days. 17.10% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of CRSP. Trustcore Financial Services LLC purchased a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $31,000. Parallel Advisors LLC bought a new stake in CRISPR Therapeutics during the fourth quarter valued at $38,000. Capital Advisory Group Advisory Services LLC grew its position in CRISPR Therapeutics by 300.0% during the fourth quarter. Capital Advisory Group Advisory Services LLC now owns 248 shares of the company's stock worth $38,000 after buying an additional 186 shares in the last quarter. Gemmer Asset Management LLC grew its position in CRISPR Therapeutics by 438.0% during the fourth quarter. Gemmer Asset Management LLC now owns 269 shares of the company's stock worth $41,000 after buying an additional 219 shares in the last quarter. Finally, Huntington National Bank increased its stake in CRISPR Therapeutics by 45.0% in the 4th quarter. Huntington National Bank now owns 290 shares of the company's stock worth $44,000 after acquiring an additional 90 shares during the last quarter. 66.43% of the stock is owned by institutional investors.
About CRISPR Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
Further Reading: EV Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]